In a retrospective analysis, Pennington et al. 7 have found that the ovarian cancer patients with germline or somatic mutations in 13 HR-associated genes (BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, FAM175A, MRE11A, NBN, PALB2, RAD51C, and RAD51D) had higher platinum sensitivity and prolonged overall survival than those without HR-associated gene mutations. The gene discussed is ATM; the disease is ovarian cancer.